{"id":"psma","name":"PSMA","symbol":"FOLH1","route":"/targets/psma/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3788","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000086205","uniprot":"https://www.uniprot.org/uniprotkb/Q04609/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/Q04609","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL1892","open-targets":"https://platform.opentargets.org/target/ENSG00000086205","civic":"https://civicdb.org/genes/2346/summary","oncokb":"https://www.oncokb.org/gene/FOLH1","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FOLH1","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=FOLH1","depmap":"https://depmap.org/portal/gene/FOLH1?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000086205-FOLH1","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/2346","omim":"https://www.omim.org/entry/600934"}],"products":[{"id":"lu177-psma-it","name":"177Lu-PSMA-I&T","status":"phase-3","modality":"Radioligand therapy (beta)","route":"/drugs/lu177-psma-it/"},{"id":"aaa817","name":"AAA817","status":"phase-3","modality":"radioligand","route":"/drugs/aaa817/"},{"id":"ac225-psma","name":"Actinium-225 PSMA agents","status":"phase-3","modality":"Targeted alpha therapy","route":"/drugs/ac225-psma/"},{"id":"florastamin-f18","name":"Florastamin F-18","status":"phase-3","modality":"PSMA-targeted PET radiotracer, fluorine-18","route":"/drugs/florastamin-f18/"},{"id":"flotufolastat","name":"Flotufolastat F-18","status":"approved","modality":"PET imaging agent","route":"/drugs/flotufolastat/"},{"id":"fpi-2265","name":"FPI-2265","status":"phase-2","modality":"radioligand","route":"/drugs/fpi-2265/"},{"id":"ga68-psma-11","name":"Gallium-68 gozetotide (PSMA-11)","status":"approved","modality":"PET imaging agent","route":"/drugs/ga68-psma-11/"},{"id":"hrs-4357","name":"HRS-4357","status":"phase-3","modality":"not stated (registered as a drug or biological on ClinicalTrials.gov)","route":"/drugs/hrs-4357/"},{"id":"illuccix","name":"Illuccix (kit for Ga-68 gozetotide)","status":"approved","modality":"PET imaging agent kit (PSMA, gallium-68)","route":"/drugs/illuccix/"},{"id":"ino-5401","name":"INO-5401","status":"phase-2","modality":"vaccine","route":"/drugs/ino-5401/"},{"id":"jnj-87189401","name":"JNJ-87189401","status":"phase-3","modality":"costimulatory bispecific antibody (PSMA x CD28, per the sponsor's pipeline page)","route":"/drugs/jnj-87189401/"},{"id":"locametz","name":"Locametz (kit for Ga-68 gozetotide)","status":"approved","modality":"PET imaging agent kit (PSMA, gallium-68)","route":"/drugs/locametz/"},{"id":"pluvicto","name":"Lutetium-177 vipivotide tetraxetan","status":"approved","modality":"Radioligand therapy (beta)","route":"/drugs/pluvicto/"},{"id":"pylarify","name":"Piflufolastat F-18 / Pylarify TruVu","status":"approved","modality":"PET imaging agent","route":"/drugs/pylarify/"},{"id":"psma-1007-f18","name":"PSMA-1007 F-18","status":"phase-3","modality":"PSMA-targeted PET radiotracer, fluorine-18","route":"/drugs/psma-1007-f18/"}],"trials":[{"id":"eclipse-psma","name":"ECLIPSE","nct":"NCT05204927","phase":"3","status":"positive"},{"id":"psmaddition","name":"PSMAddition","nct":"NCT04720157","phase":"3","status":"positive"},{"id":"splash","name":"SPLASH","nct":"NCT04647526","phase":"3","status":"mixed"},{"id":"psmafore","name":"PSMAfore","nct":"NCT04689828","phase":"3","status":"positive"},{"id":"psma-prerp","name":"PSMA-PreRP","nct":"NCT03368547","phase":"3","status":"positive"},{"id":"vision","name":"VISION","nct":"NCT03511664","phase":"3","status":"positive"},{"id":"nct05936658","name":"[18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer","nct":"NCT05936658","phase":"3","status":"active"},{"id":"nct07311694","name":"A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer","nct":"NCT07311694","phase":"3","status":"recruiting"},{"id":"mcrpc","name":"A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)","nct":"NCT07164443","phase":"3","status":"recruiting"},{"id":"nct07611110","name":"AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)","nct":"NCT07611110","phase":"3","status":"recruiting"},{"id":"nct06122584","name":"Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer","nct":"NCT06122584","phase":"3","status":"recruiting"},{"id":"nct05004285","name":"Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis","nct":"NCT05004285","phase":"3","status":"active"},{"id":"nct07052214","name":"PSMA PET Combined With MRI for the Detection of PCa","nct":"NCT07052214","phase":"3","status":"recruiting"},{"id":"nct04457245","name":"Randomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer","nct":"NCT04457245","phase":"3"},{"id":"nct06855277","name":"Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC","nct":"NCT06855277","phase":"3","status":"recruiting"},{"id":"nct03739684","name":"Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer","nct":"NCT03739684","phase":"3","status":"completed"},{"id":"nct06754085","name":"Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer","nct":"NCT06754085","phase":"3","status":"recruiting"},{"id":"nct06780670","name":"Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy","nct":"NCT06780670","phase":"2/3","status":"recruiting"},{"id":"nct05381103","name":"PSMA-PET to Guide Prostatectomy","nct":"NCT05381103","phase":"2/3","status":"recruiting"},{"id":"nct02981368","name":"Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer","nct":"NCT02981368","phase":"2/3","status":"completed"},{"id":"therap","name":"TheraP (ANZUP 1603)","nct":"NCT03392428","phase":"2","status":"positive"},{"id":"alphabreak","name":"AlphaBreak (FPI-2265) & AcTION (225Ac-PSMA-617)","nct":"NCT06402331","phase":"2","status":"active"},{"id":"nct06894511","name":"An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC","nct":"NCT06894511","phase":"2","status":"active"},{"id":"nct07455903","name":"Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT","nct":"NCT07455903","phase":"2","status":"recruiting"},{"id":"nct07285057","name":"Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance","nct":"NCT07285057","phase":"2","status":"recruiting"},{"id":"nct06909825","name":"FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","nct":"NCT06909825","phase":"2","status":"active"},{"id":"nct06617481","name":"PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence","nct":"NCT06617481","phase":"2","status":"recruiting"},{"id":"nct06004661","name":"Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function","nct":"NCT06004661","phase":"2","status":"active"},{"id":"nct05219500","name":"Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).","nct":"NCT05219500","phase":"2","status":"active"},{"id":"nct07258407","name":"A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer","nct":"NCT07258407","phase":"1/2","status":"recruiting"},{"id":"nct06383052","name":"A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC","nct":"NCT06383052","phase":"1/2","status":"active"},{"id":"nct06906471","name":"A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS","nct":"NCT06906471","phase":"1/2","status":"recruiting"},{"id":"nct07567521","name":"A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC","nct":"NCT07567521","phase":"1/2","status":"recruiting"},{"id":"nct03491683","name":"INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)","nct":"NCT03491683","phase":"1/2","status":"active"},{"id":"nct05682443","name":"ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC","nct":"NCT05682443","phase":"1/2","status":"active"},{"id":"nct07590934","name":"Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer","nct":"NCT07590934","phase":"1/2","status":"recruiting"}],"pathways":["prostate-cancer-signalling"],"companies":["abx-advanced-biochemical-compounds","advanced-accelerator-applications","arsenal-bio","artbio","astrazeneca","bayer","blue-earth-diagnostics","clarity-pharmaceuticals","convergent-therapeutics","curium","fusion-pharma","inovio","janux-therapeutics","hengrui","johnson-johnson","lantheus","novartis","perspective-therapeutics","point-biopharma","telix","xilio-therapeutics"],"keyPapers":["paper-therap-lancet-2021","paper-psma-prerp-hope-jama-oncol-2021","paper-vision-nejm-2021","paper-propsma-hofman-lancet-2020","paper-fendler-psma-pet-biochemical-recurrence-jama-oncol-2019","paper-silver-psma-expression-normal-malignant-tissues-ccr-1997"],"hotspots":[],"openQuestions":[{"id":"psma-earlier-alpha","question":"Should PSMA radioligand therapy move to hormone-sensitive disease, and is an alpha emitter better than lutetium-177?","stage":"clinical","actor":"industry","source":{"label":"VISION, NEJM 2021","url":"https://doi.org/10.1056/NEJMoa2107322"}}],"assays":[{"id":"psma-pet-selection","name":"PSMA PET (Ga-68 PSMA-11, F-18 piflufolastat, F-18 flotufolastat)","cutoff":"At least one PSMA-positive lesion and no dominant PSMA-negative lesion (VISION criteria) for lutetium-177 PSMA-617"}],"resistance":[{"class":"ar-pathway","mechanism":"AR amplification and ligand-binding-domain mutations","category":"on-target"},{"class":"ar-pathway","mechanism":"AR splice variants (AR-V7)","category":"on-target"},{"class":"ar-pathway","mechanism":"Lineage plasticity to neuroendocrine prostate cancer","category":"lineage"},{"class":"ar-pathway","mechanism":"PI3K/AKT activation via PTEN loss","category":"bypass"},{"class":"ar-pathway","mechanism":"Glucocorticoid receptor substitution","category":"bypass"}],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}